Related Experiment Video
Updated: Jun 24, 2025
08:27
Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice
Published on: March 11, 2020
6.2K
[Uric acid, cognitive disorders, neurodegeneration]
M S Eliseev1, O V Zheliabina1, E L Nasonov1,2
1Nasonova Research Institute of Rheumatology.
Terapevticheskii Arkhiv
|June 3, 2024
Summary
Uric acid (UA) shows potential neuroprotective properties, influencing cognitive function and neurodegeneration. Further research is needed to determine optimal UA levels for preventing cognitive impairment.
Area of Science:
- Neuroscience
- Biochemistry
- Gerontology
Background:
- Uric acid (UA) is a key antioxidant in the body.
- Its dual role as antioxidant and prooxidant is implicated in neurodegenerative diseases.
- Serum UA levels are increasingly studied in relation to cognitive health.
Purpose of the Study:
- To examine the role of uric acid in cognitive changes and neurodegeneration.
- To explore the antioxidant and prooxidant functions of UA in the brain.
- To understand the relationship between serum UA levels and cognitive impairment.
Main Methods:
- Literature review of studies investigating uric acid and cognitive function.
- Analysis of research on UA's role in neurodegenerative conditions like Alzheimer's disease.
- Examination of the balance between UA's antioxidant and prooxidant activities.
Main Results:
- Changes in serum UA levels correlate with cognitive impairment development or delay.
- UA exhibits potential neuroprotective properties, impacting cognitive function dynamics.
- The balance of UA's antioxidant/prooxidant roles is crucial for neuronal protection.
Conclusions:
- Uric acid metabolism is linked to brain health and cognitive processes.
- Further research is essential to clarify UA's complex role and establish optimal levels.
- Understanding UA's impact may lead to new strategies for preventing cognitive decline.
Related Concept Videos
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:28Disorders of the Nervous Tissue
1.1K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.1K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:23Role of Neurotransmitters in Memory
523
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
523
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110